True North Therapeutics to Present Clinical Data in Patients with Cold Agglutinin Disease (CAD) for Lead Product Candidate TNT009
Late-Breaking Data from Ongoing Phase 1b Clinical Study to be Presented at 21st Congress of the European Hematology Association in Copenhagen
South San Francisco, CA, May 19, 2016— True North Therapeutics, a clinical stage biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, today announced that a late-breaking abstract describing clinical data from its ongoing Phase 1b clinical study of TNT009 in patients with Cold Agglutinin Disease (CAD) has been selected for presentation at the 21st Congress of the European Hematology Association (EHA) held June 9-12, 2016 in Copenhagen. The abstract describes clinical data related to the Company’s lead product candidate, TNT009, a first-in-class monoclonal antibody that selectively inhibits the Classical Complement pathway by targeting C1s, a serine protease within the C1-complex in the Complement pathway of the immune system.
“We are excited to share these data demonstrating the robust activity of TNT009 in patients with Cold Agglutinin Disease,” said Nancy Stagliano, PhD, Chief Executive Officer of True North. “True North is committed to the accelerated development of a new therapeutic for patients who suffer from this rare form of autoimmune hemolytic anemia.”
|Title:||The Anti C1S Complement Antibody TNT009 Induces Rapid Complete Remissions of Anaemia in Patients with Primary Cold Agglutinin Disease|
|Author:||Jäger, Medical University of Vienna|
|Late Breaking Session:||Topic: 26. Red blood cells and iron – Clinical|
|Date/Time:||Sunday, June 12, 2016, 12:15 – 12:30 CET|
About Cold Agglutinin Disease (CAD)
CAD is an autoimmune hemolytic anemia in which autoantibodies target and destroy red blood cells, causing anemia, fatigue and potentially fatal thrombosis. The prevalence of primary CAD is approximately twenty per million. There are limited treatment options available and many of these patients, despite therapy, have moderate to severe anemia. True North sponsors a patient registry for CAD and other autoimmune hemolytic anemias, called the COMPASS Registry (https://www.compassregistry.org/), dedicated to advancing a deeper understanding of these diseases, engaging with patients, and supporting clinical trial recruitment.
TNT009 is a first-in-class monoclonal antibody that selectively inhibits the Classical Complement pathway by targeting C1s, a serine protease within the C1-complex in the Complement pathway of the immune system. TNT009 thereby prevents downstream disease processes involving phagocytosis, inflammation, and cell lysis. With a unique mechanism of action and high target specificity, TNT009 selectively inhibits disease processes in the Classical Complement pathway while maintaining the important immune surveillance provided by the Alternative Complement Pathway and Lectin Complement Pathway. TNT009 is currently in clinical development for the treatment of Cold Agglutinin Disease (CAD), a rare disease in hematology. Because numerous other diseases are known to share the basic underlying mechanism addressed by TNT009, the potential for other indications is clear.
About True North Therapeutics
True North Therapeutics is a clinical stage biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in rare diseases with high unmet need. The company’s lead drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of rare diseases mediated by the Complement system in hematology, transplantation, and dermatology. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.
The Yates Network